Abstract: The present invention relates to a method of treatment and/or ameliorating the symptoms of Huntington's disease comprising the step of administering an effective amount of adenosine triphosphate, co-carboxylase, nicotinamide, and cyanocobalamin in a physiologically acceptable carrier to an individual in need thereof. Preferably, the administration is via intramuscular injection.

Abstract: A method of treating mild atopic dermatitis patients by locally administering an external composition containing adenosylcobalamin as an active ingredient is provided. The composition can effectively treat mild atopic dermatitis patients without side effects.

Abstract: The present invention relates to new rhenium compounds of formula (I) with medical utility, corresponding pharmaceutical compositions as well as medical uses thereof.

Abstract: Provided herein are methods and systems for identifying one or more cofactors such as vitamins for individuals based on the genetic makeup of the individual by detecting the presence or absence of at least one genetic variant, determining a predisposition to cofactor remediable condition, generating a personalized nutritional advice plan based on the genetic variant. Also provided herein are formulations of cofactors determined by the genetic make-up of the individual and methods of determining and producing these formulations.

Abstract: The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds.

Abstract: Polymeric platinum amidomalonate complexes, where the platinum is in +2 or +4 oxidation state, and where the complexes optionally contain tumor seeking groups, are useful in the treatment of cancer.

Abstract: Compositions and methods of SIRT activation are presented in which one or more vitamin compounds, and especially vitamin B compounds are used to significantly increase SIRT activity in vitro and in vivo. In especially preferred compositions, vitamin B6, vitamin B12, and vitamin B2 are present in synergistic quantities.

Abstract: A method for producing a fermentation product from a lignocellulose-containing material comprises pre-treating the lignocellulose-containing material; introducing a cationic polysaccharide to the pre-treated lignocellulose-containing material; exposing the pre-treated lignocellulose-containing material to an effective amount of a first hydrolyzing enzyme; and fermenting with a fermenting organism to produce a fermentation product. The cationic polysaccharide may be a cationic starch.

Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.

Abstract: A method and medical composition for the treatment and/or prevention of a functional Vitamin B12 deficiency in an individual that is brought about as a consequence of oxidative stress on biochemical pathways. The functional Vitamin B12 deficiency may eventually present as dementia, other neuropsychiatric abnormality and/or vascular disease. The method involves the administration of a medical composition that supplies a cobalt-sulphur bond in the upper ?-ligand of an intracellular cobalamin molecule thereby facilitating intracellular processing of cobalamin. The cobalt-sulphur bond may he provided directly by administration of a thiolatocohalamin, such as glutathianyl-cobalamin or indirectly by the co-administration of Vitamin B12 (or a derivative thereof) with a sulphur-containing molecule, such as glutathione or a precursor thereof.

Abstract: The invention relates to preparations comprising vitamin B12 and a butanol, and to the use of butanol for stabilizing vitamins.

Abstract: Carbonyl compounds generated and accumulated in the peritoneal dialysate can be inactivated or eliminated by a carbonyl compound-trapping agent such as aminoguanidine. Carbonyl compounds generated during sterilization and storage of the peritoneal dialysate can be eliminated by pre-contacting with the trapping agent. Further, it is possible to eliminate carbonyl compounds transferred from the blood to the peritoneal cavity of the patient during peritoneal dialysis treatment, by adding the trapping agent to the peritoneal dialysate or by circulating the fluid through a carbonyl compound-trapping cartridge. Intraperitoneal protein modification by carbonyl compounds is inhibited by the present invention, thereby sufficiently reducing peritoneal disorders associated with peritoneal dialysis treatment.

Abstract: The present invention relates to a method for determining absorption of cobalamin or analogues thereof in an individual comprising (ii providing two blood samples from said individual, wherein the first sample comprises said individual's blood prior to ingestion by said individual of non-radioactive cobalamin or an analogue thereof and the second sample comprises said individual's blood after said ingestion, (ii) determining the concentration of cobalamin or analogue thereof in the first sample, (iii) determining the concentration of cobalamin or analogue thereof in the second sample by treating complexes of cobalamin or analogue thereof and one or more carrier proteins with one or more enzymes to release cobalamin or analogue thereof from said one or more carrier proteins, and (iv) determining, on the basis of comparison of said concentrations in said two samples, whether said cobalamin or analogue thereof has been absorbed in the blood stream.

Abstract: The invention relates to cobalamin derivatives having no or low binding affinity to the transport protein transcobalamin II (TCII) and retaining activity as a vitamin B12 substitute, optionally carrying a therapeutic and/or diagnostic agent, such as a radioactive metal. These compounds have a much reduced accumulation rate in blood and benign organs, such as kidney and liver, compared to the accumulation rate in neoplastic tissues, and are more rapidly eliminated from blood. The invention further relates to a method of diagnosis and a method of treatment of a neoplastic disease or an infection by microorganisms in a mammal by exposing the mammal to a period of a vitamin B12 free diet, and subsequently applying a cobalamin derivative of the invention carrying a diagnostic and/or therapeutic agent. By selecting cobalamin derivatives acting as vitamin B12 substitutes, the risk of the formation of resistant off-spring in neoplastic tissue is much reduced.

Abstract: A compound useful for in vivo imaging of organs and tumors is provided of formula: wherein is a cobalamin, is derived from a corrin carboxylic acid group of said cobalamin, Y is a linking group and X is a chelating group, optionally comprising a detectable radionuclide or a paramagnetic metal ion, and n is 1-3.

Abstract: The present invention relates to a composition for external application for improving a skin disease (e.g. psoriasis). Said composition contains adenosyl cobalamin (coenzyme B12), opt. in admixture with other cobalamins. Preferable said composition is present in the form of liposomal preparations, which are made of a phospholipid and cholesterol.

Abstract: An agent, composition and method for the treatment, prophylaxis and/or diagnosis of proliferative disorders, which is highly and efficiently absorbed at the site of abnormal cellular proliferation is disclosed.

Abstract: The invention provides cobalamin compounds linked to a neutron capture therapy target (e.g. Boron-10 or Gadolinium-157), and optionally linked to a detectable moiety, as well as pharmaceutical compositions comprising the compounds, and methods for using the compounds in medical diagnosis and therapy.

Abstract: The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds.

Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.

Abstract: The invention provides a diagnostic or prognostic assay method for Alzheimer's Disease by assaying a body fluid sample or a test sample derived therefrom for holo-trancobalamin II.

Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.

Abstract: The invention provides detectably labeled cobalamin derivatives which are useful for medical treatment and diagnosis.

Abstract: Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compounds in combination with anti-viral, anti-proliferative and anti-inflammatory compounds. Vitamin B12 compounds are administered separately, simultaneously or in combination with anti-viral, anti-proliferative and/or anti-inflammatory compounds to provide an enhanced therapeutic effect for treating viral, proliferative and inflammatory diseases.

Abstract: The invention provides detectably labeled cobalamin derivatives which are useful for medical treatment and diagnosis.

Abstract: An endogenous plasmid of Propionibacterium is described, isolated from Propionibacteria freudenreichii LMG 16545 (deposited as CBS 101022), and its sequence provided. This plasmid can be used to transform Propionibacteria to express homologous or heterologous proteins, in the production of recombinant proteins or products of enzymes, for example vitamin B12.

Abstract: The invention provides cobalamin compounds linked to a neutron capture therapy target (e.g. Boron-10 or Gadolinium-157), and optionally linked to a detectable moiety, as well as pharmaceutical compositions comprising the compounds, and methods for using the compounds in medical diagnosis and therapy.

Abstract: The present invention is directed to compositions and methods for affecting metallocorrinoid uptake. The compositions and methods of the present invention are particularly useful in enhancing the uptake or availability of biologically active metallocorrinoids (e.g. cobalamin and its analogs). The present invention is particularly useful in the treatment or prevention of conditions that result from low expression or activity of proteins involved in the processing of metallocorrinoids, as well as in conditions which would benefit from enhanced uptake or availability of cobalamin or its biologically active analogs of cobalamin (e.g. cobalamin drug conjugates).

Abstract: Disclosed are novel bicyclic tris(anhydride)s useful as intermediates in the synthesis of biologically active compounds, and the compounds which may be synthesized from such intermediates.

Abstract: A vitamin B12 supplement composition comprising vitamin B12 with and/or without added folic acid that is essentially free of antioxidants, such as vitamin C, as well as iron is disclosed. Also disclosed are methods of using this vitamin composition to prevent brain and nervous system damage, such as peripheral nerve damage, as well as pernicious anemia, such as where such anemia is caused by a deficiency of vitamin B12 deficiency.

Abstract: A vitamin B12 supplement composition comprising vitamin B12 with and/or without added folic acid that is essentially free of antioxidants, such as vitamin C, as well as iron is disclosed. Also disclosed are methods of using this vitamin composition to prevent brain and nervous system damage, such as peripheral nerve damage, as well as pernicious anemia, such as where such anemia is caused by a deficiency of vitamin B12 deficiency.

Abstract: The invention describes complexes between VB12 analogues and either GCSF or EPO that retain both significant affinity for intrinsic factor (IF) in the VB12 portion of the complex and significant bioactivity of the GCSF or EPO portion of the complex. The invention also concerns a process for the synthesis of these complexes. This is achieved at least in part, by using a spacer compound, which is linked covalantly between the VB12 portion and the GCSF or EPO.

Abstract: Vitamin B12 is administered to allergy patients via mucosal membranes in a series of lozenges and other patient friendly transmucosal modes of delivery given repeatedly over a period of time to reduce the symptoms and IgE antibodies associated with allergic diseases such as allergic rhinitis (hay fever), and allergic asthma.

Abstract: The present invention provides a process for the preparation of a composition comprising natural vitamin B12, wherein said process comprises the steps of: a) obtaining microbial cells containing natural vitamin B12, b) causing opening of the microbial cells such that at least part of the soluble content of the cells comprising vitamin B12 is released in a liquid in which the cells are contained, c) separating the opened cells and the liquid comprising the vitamin B12, d) preparing a mixture of the vitamin B12 and at least a part of the opened cells, wherein the mixture has a vitamin B12 concentration on dry matter in excess of 0.1% (w/w).